Wells Fargo Upgrades Relay Therapeutics and Zymeworks Stocks
Wells Fargo upgrades Relay Therapeutics and Zymeworks, raising price targets and highlighting potential 2026 growth from clinical data and cancer treatment opportunities.
/ 9 items
#ZYME↓
Zymeworks & Jazz Pharmaceuticals Stocks Surge on Positive Cancer Trial Results
Zymeworks jumps 31% and Jazz Pharmaceuticals rises 26% after announcing successful Phase 3 trial results for Ziihera cancer treatment targeting stomach and esophageal cancers.
H.C. Wainwright Rates Zymeworks a Buy on Promising ZW191 Cancer Drug Data
H.C. Wainwright sets $26 price target for Zymeworks after Phase 1 data shows ZW191 cancer drug outperforms FDA-approved competitor with 44% response rate.